281 related articles for article (PubMed ID: 33064050)
1. A safety evaluation of aripiprazole in the treatment of schizophrenia.
Preda A; Shapiro BB
Expert Opin Drug Saf; 2020 Dec; 19(12):1529-1538. PubMed ID: 33064050
[TBL] [Abstract][Full Text] [Related]
2. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
[No Abstract] [Full Text] [Related]
3. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
Rapinesi C; Kotzalidis GD; Mazzarini L; Brugnoli R; Ferracuti S; De Filippis S; Cuomo I; Giordano G; Del Casale A; Angeletti G; Sani G; Girardi P
Clin Drug Investig; 2019 Aug; 39(8):713-735. PubMed ID: 31152368
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole Lauroxil: A Review in Schizophrenia.
Frampton JE
Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.
Shirley M; Perry CM
Drugs; 2014 Jul; 74(10):1097-110. PubMed ID: 24969315
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
Aggarwal A; Gopalakrishna G; Lauriello J
Clin Schizophr Relat Psychoses; 2016; 10(1):58-63. PubMed ID: 27074333
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
Potkin SG; Preda A
Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
Citrome L
Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
[TBL] [Abstract][Full Text] [Related]
10. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
Risinger R; Hard M; Weiden PJ
Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337
[TBL] [Abstract][Full Text] [Related]
11. The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia.
Kahn RS; Giannopoulou A
Expert Rev Neurother; 2015; 15(9):969-81. PubMed ID: 26289486
[TBL] [Abstract][Full Text] [Related]
12. Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists.
Fagiolini A; Alfonsi E; Amodeo G; Cenci M; Di Lella M; Farinella F; Ferraiuolo F; Fraguas D; Loparco N; Gutierrez-Rojas L; Mignone ML; Pataracchia G; Pillai G; Russo F; Sanchez-Gistau V; Spinogatti F; Toscano M; Villari V; De Filippis S
Expert Opin Drug Saf; 2016; 15(4):449-55. PubMed ID: 26886162
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
[TBL] [Abstract][Full Text] [Related]
14. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
Weiden PJ; Du Y; Liu CC; Stanford AD
CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
Eum S; Schneiderhan ME; Brown JT; Lee AM; Bishop JR
BMC Psychiatry; 2017 Jul; 17(1):238. PubMed ID: 28673279
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole Lauroxil NanoCrystal
Ehret MJ; Davis E; Luttrell SE; Clark C
Clin Schizophr Relat Psychoses; 2018; 12(2):92-96. PubMed ID: 30040476
[TBL] [Abstract][Full Text] [Related]
18. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
[TBL] [Abstract][Full Text] [Related]
19. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
Citrome L
Expert Rev Neurother; 2017 Oct; 17(10):1029-1043. PubMed ID: 28832262
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]